Purpose Of Review: Diabetic retinopathy (DR) is one of the leading causes of preventable vision loss in the world and its prevalence continues to increase worldwide. One of the ultimate and visually impairing complications of DR is proliferative diabetic retinopathy (PDR) and subsequent tractional retinal detachment. Treatment modalities, surgical techniques, and a better understanding of the pathophysiology of DR and PDR continue to change the way we approach the disease. The goal of this review is to provide an update on recent treatment modalities and outcomes of proliferative diabetic retinopathy and its complications including tractional retinal detachment.
Recent Findings: Panretinal photocoagulation (PRP), anti-vascular endothelial growth factor (anti-VEGF), and pars plana vitrectomy are the mainstay of PDR treatment. However, PRP and anti-VEGF are associated with significant treatment burden and multiple subsequent treatments. Early vitrectomy is associated with vision preservation, less treatment burden, and less subsequent treatments than therapy with PRP and anti-VEGF.
Summary: Concerning costs, high rates of noncompliance in the diabetic population and significant rates of subsequent treatments with initial PRP and anti-VEGF, early vitrectomy for diabetic retinopathy in patients at risk of PDR is a cost-effective long-term stabilizing treatment for diabetics with advanced disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ICU.0000000000000760 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association between glucagon-like peptide-1 agonists and risk of diabetic retinopathy: a disproportionality analysis using FDA adverse event reporting system data.
Expert Rev Endocrinol Metab
January 2025
Department of Pharmacology, Moti Lal Nehru Medical College, Allahabad, India.
Background: Glucagon-like peptide-1 (GLP-1) agonists are commonly prescribed for type 2 diabetes mellitus (T2DM). Concerns have emerged regarding their potential link to diabetic retinopathy (DR).
Methods: To evaluate the association between GLP-1 agonists and DR, a disproportionality analysis was conducted using FDA Adverse Event Reporting System (FAERS) data from Q4/2003 to Q2/2024 via OpenVigil 2.
The Pathophysiology and Vascular Complications of Diabetes in Chronic Kidney Disease: A Comprehensive Review.
Cureus
December 2024
Neurosurgery, Federal Fluminense University, Niterói, BRA.
The coexistence of type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) represents a significant global health challenge, contributing to substantial morbidity, mortality, and economic burden. T2DM is the leading cause of CKD, and CKD exacerbates diabetes-related complications, creating a bidirectional relationship driven by oxidative stress, inflammation, and endothelial dysfunction. Diabetic kidney disease (DKD), affecting some individuals with T2DM, accelerates progression to end-stage renal disease (ESRD) and increases cardiovascular mortality.
View Article and Find Full Text PDFModelling neurodegeneration and inflammation in early diabetic retinopathy using 3D human retinal organoids.
In Vitro Model
February 2024
iNOVA4Health, NOVA Medical School|Faculdade de Ciências Médicas, NMS|FCM, Universidade Nova de Lisboa, Rua Camara Pestana, 6, Lisbon, Portugal.
Purpose: Diabetic retinopathy (DR) is a complication of diabetes and a primary cause of visual impairment amongst working-age individuals. DR is a degenerative condition in which hyperglycaemia results in morphological and functional changes in certain retinal cells. Existing treatments mainly address the advanced stages of the disease, which involve vascular defects or neovascularization.
View Article and Find Full Text PDFEales' Disease in Inuit: A Short Report and Clinical Update.
Int Med Case Rep J
January 2025
Department of Ophthalmology, Rigshospitalet-Glostrup, Glostrup, Denmark.
Purpose: We report a case of Eales disease in Inuit and reflect on advances in telemedicine and treatment of retinal disease since the first report of Eales' disease in Greenlandic Inuit was published.
Patients And Methods: A 41-year-old Inuit female complaining of blurred vision was referred to our eye department. There had been no sign of diabetic retinopathy during diabetic eye screening and the patient had been treated for tuberculosis in 2010.
Metabolic Fingerprint of Dual Body Fluids Deciphers Diabetic Retinopathy.
Small
January 2025
Department of Ophthalmology, National Clinical Research Center for Eye Diseases, Shanghai Gene Therapy Center, Shanghai Key Laboratory of Ocular Fundus Disease, Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200040, P. R. China.
Diabetic retinopathy (DR) is a microvascular complication of diabetes, affecting 34.6% of diabetes patients worldwide. Early detection and timely treatment can effectively improve the prognosis of DR.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!